摘要:
目的 比较5种β-内酰胺类药物分别联合阿奇霉素治疗支原体肺炎合并细菌感染的成本效果。 方法 采用回顾性研究方法，分别统计5种治疗方案的有效率、治疗成本和成本效果比，对其进行经济学评价。 结果 5组的有效率分别为97.29%、100%、96.55%、95.65%、97.36%；成本分别为（2 831.13±910.16）元、（2 816.31±127.11）元、（3 453.29±645.89）元、（4 382.42±1 484.26）元、（3 703.39±124.86）元；成本效果比分别为（29.10±9.36）、（28.16±5.24）、（35.77±6.69）、（38.04±7.90）、（35.26±10.10）。 结论 从药物经济学的角度考虑，B组头孢匹胺联合阿奇霉素的成本及成本效果比均最低，最具有成本效果优势，是治疗儿童支原体肺炎合并细菌感染的首选治疗方案。
Abstract:
Objective To evaluate the cost and effectiveness for five combination therapy of β-lactam antibiotic with azithromycin in the treatment of mycoplasma pneumonia (MP) complicated with bacterial infection. Methods A retrospective study was conducted to compare the cost and effectiveness of the five regimens. Results The effective rates of group A, B, C, D and E were 97.29%, 100%, 96.55%, 95.65% and 97.36% respectively. The costs were (2 831.13±910.16) yuan,(2 816.31±127.11) yuan,(3 453.29±645.89) yuan,(4 382.42±1484.26) yuan,(3 703.39±124.86) yuan respectively. The cost-effectiveness ratios were (29.10±9.36), (28.16±5.24), (35.77±6.69), (38.04±7.90)and (35.26±10.10)respectively. Conclusion In terms of pharmacoeconomics, the combination of cefpiramide with azithromycin in group B has the lowest cost and cost-effectiveness ratio. This regimen is the most effective and economically favored combination. It is the treatment of first choice for pediatric MP patients complicated with bacterial infection.
点击查看大图
下载:
